Division of Pulmonology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Republic of Korea.
Cancer Chemother Pharmacol. 2013 Oct;72(4):809-14. doi: 10.1007/s00280-013-2256-0. Epub 2013 Aug 6.
Belotecan is a new camptothecin analogue and a potent topoisomerase I inhibitor. The aim of this phase II study was to investigate the efficacy and toxicity of belotecan in previously untreated elderly patients with small cell lung cancer (SCLC).
A total of 26 patients, aged ≥65 years, with previously untreated, extensive-stage SCLC were enrolled in the study. Belotecan was administered by daily intravenous infusion at 0.5 mg/m(2)/day for 5 consecutive days every 3 weeks.
The overall response rate and disease control rate of chemotherapy on an intention-to-treat basis were 35 and 54 %, respectively. The median overall survival was 6.4 months, and the median time to progression was 2.8 months. The most common toxicity was hematologic. Grade 3 or 4 neutropenia occurred in 80.8 % of patients, and grade 3 or 4 thrombocytopenia in 15.3 %. Non-hematologic toxic effects of grade 3 or 4 were uncommon.
Belotecan had modest efficacy and well-tolerated toxicity in previously untreated, elderly SCLC patients. Single belotecan could be a promising treatment option, considering its lower toxicity in elderly patients who are unsuitable candidates for platinum plus etoposide chemotherapy.
贝洛替康是一种新型喜树碱类似物，也是一种有效的拓扑异构酶 I 抑制剂。本 II 期研究旨在评估贝洛替康在未经治疗的老年广泛期小细胞肺癌（SCLC）患者中的疗效和毒性。
共纳入 26 例年龄≥65 岁、未经治疗的广泛期 SCLC 患者，接受贝洛替康 0.5mg/m²/日静脉滴注，连续 5 天，每 3 周 1 次。
根据意向治疗原则，化疗的总缓解率和疾病控制率分别为 35%和 54%。中位总生存期为 6.4 个月，中位无进展生存期为 2.8 个月。最常见的毒性是血液学毒性。80.8%的患者发生 3 或 4 级中性粒细胞减少症，15.3%的患者发生 3 或 4 级血小板减少症。非血液学毒性的 3 或 4 级不良反应不常见。
贝洛替康在未经治疗的老年 SCLC 患者中具有一定的疗效，且毒性可耐受。考虑到老年患者对铂类加依托泊苷化疗不耐受，贝洛替康的低毒性可能使其成为一种有前途的治疗选择。
